» Articles » PMID: 22396170

FGF19 and Cancer

Overview
Date 2012 Mar 8
PMID 22396170
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play critical roles in a variety of normal developmental and physiological processes. Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression. The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans. This chapter focuses on recent progress in the understanding of the molecular mechanisms of FGF19 action and its potential involvement in cancer.

Citing Articles

FGF19-Activated Hepatic Stellate Cells Release ANGPTL4 that Promotes Colorectal Cancer Liver Metastasis.

Fan X, Li B, Zhang F, Liu M, Kwan H, Liu Z Adv Sci (Weinh). 2024; 12(7):e2413525.

PMID: 39716892 PMC: 11831508. DOI: 10.1002/advs.202413525.


Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets.

Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium Cancers (Basel). 2024; 16(5).

PMID: 38473265 PMC: 10931414. DOI: 10.3390/cancers16050901.


Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions.

Zhu Y, Tang S, Yuan Q, Fu J, He J, Liu Z Cell Rep Med. 2024; 5(2):101375.

PMID: 38278146 PMC: 10897507. DOI: 10.1016/j.xcrm.2023.101375.


Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients.

Xu J, Cui J, Jiang H, Zeng Y, Cong X Cancer Med. 2023; 12(7):7762-7771.

PMID: 36622048 PMC: 10134273. DOI: 10.1002/cam4.5532.


Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein.

Park J, Choi J, Cao L, Mohanty J, Suzuki Y, Park A Cell Rep. 2022; 41(4):111545.

PMID: 36288716 PMC: 9636537. DOI: 10.1016/j.celrep.2022.111545.